Literature DB >> 28068482

Metabolic Reprogramming in Brain Tumors.

Sriram Venneti1, Craig B Thompson2.   

Abstract

Next-generation sequencing has substantially enhanced our understanding of the genetics of primary brain tumors by uncovering several novel driver genetic alterations. How many of these genetic modifications contribute to the pathogenesis of brain tumors is not well understood. An exciting paradigm emerging in cancer biology is that oncogenes actively reprogram cellular metabolism to enable tumors to survive and proliferate. We discuss how some of these genetic alterations in brain tumors rewire metabolism. Furthermore, metabolic alterations directly impact epigenetics well beyond classical mechanisms of tumor pathogenesis. Metabolic reprogramming in brain tumors is also influenced by the tumor microenvironment contributing to drug resistance and tumor recurrence. Altered cancer metabolism can be leveraged to noninvasively image brain tumors, which facilitates improved diagnosis and the evaluation of treatment effectiveness. Many of these aspects of altered metabolism provide novel therapeutic opportunities to effectively treat primary brain tumors.

Entities:  

Keywords:  IDH mutation; glioma; glucose; glutamine; imaging; treatment

Mesh:

Year:  2016        PMID: 28068482     DOI: 10.1146/annurev-pathol-012615-044329

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  31 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 2.  Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies.

Authors:  Chan-Wang J Lio; Hiroshi Yuita; Anjana Rao
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

3.  Deletion of Neuronal GLT-1 in Mice Reveals Its Role in Synaptic Glutamate Homeostasis and Mitochondrial Function.

Authors:  Laura F McNair; Jens V Andersen; Blanca I Aldana; Michaela C Hohnholt; Jakob D Nissen; Yan Sun; Kathryn D Fischer; Ursula Sonnewald; Nils Nyberg; Sophie C Webster; Kush Kapur; Theresa S Rimmele; Ilaria Barone; Hannah Hawks-Mayer; Jonathan O Lipton; Nathaniel W Hodgson; Takao K Hensch; Chiye J Aoki; Paul A Rosenberg; Helle S Waagepetersen
Journal:  J Neurosci       Date:  2019-03-29       Impact factor: 6.167

4.  Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.

Authors:  Michal Hlavac; Annika Dwucet; Richard Eric Kast; Jens Engelke; Mike-Andrew Westhoff; Markus D Siegelin; Klaus-Michael Debatin; Christian Rainer Wirtz; Marc-Eric Halatsch; Georg Karpel-Massler
Journal:  Cell Oncol (Dordr)       Date:  2019-03-11       Impact factor: 6.730

Review 5.  Metabolic heterogeneity and adaptability in brain tumors.

Authors:  Christian E Badr; Daniel J Silver; Florian A Siebzehnrubl; Loic P Deleyrolle
Journal:  Cell Mol Life Sci       Date:  2020-06-06       Impact factor: 9.261

6.  Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells.

Authors:  Xiuxing Wang; Kailin Yang; Qiulian Wu; Leo J Y Kim; Andrew R Morton; Ryan C Gimple; Briana C Prager; Yu Shi; Wenchao Zhou; Shruti Bhargava; Zhe Zhu; Li Jiang; Weiwei Tao; Zhixin Qiu; Linjie Zhao; Guoxing Zhang; Xiqing Li; Sameer Agnihotri; Paul S Mischel; Stephen C Mack; Shideng Bao; Jeremy N Rich
Journal:  Sci Transl Med       Date:  2019-08-07       Impact factor: 17.956

7.  Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.

Authors:  David Schiff; Martin Van den Bent; Michael A Vogelbaum; Wolfgang Wick; C Ryan Miller; Martin Taphoorn; Whitney Pope; Paul D Brown; Michael Platten; Rakesh Jalali; Terri Armstrong; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

8.  Toxic effects of phytol and retinol on human glioblastoma cells are associated with modulation of cholesterol and fatty acid biosynthetic pathways.

Authors:  Gustavo Facchini; Raffaela Silvestre Ignarro; Erika Rodrigues-Silva; André Schwambach Vieira; Iscia Lopes-Cendes; Roger Frigério Castilho; Fabio Rogerio
Journal:  J Neurooncol       Date:  2017-11-20       Impact factor: 4.130

9.  Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.

Authors:  Chan Chung; Stefan R Sweha; Drew Pratt; Benita Tamrazi; Pooja Panwalkar; Adam Banda; Jill Bayliss; Debra Hawes; Fusheng Yang; Ho-Joon Lee; Mengrou Shan; Marcin Cieslik; Tingting Qin; Christian K Werner; Daniel R Wahl; Costas A Lyssiotis; Zhiguo Bian; J Brad Shotwell; Viveka Nand Yadav; Carl Koschmann; Arul M Chinnaiyan; Stefan Blüml; Alexander R Judkins; Sriram Venneti
Journal:  Cancer Cell       Date:  2020-08-13       Impact factor: 31.743

10.  Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas.

Authors:  Victor Ruiz-Rodado; Tathiane M Malta; Tomohiro Seki; Adrian Lita; Tyrone Dowdy; Orieta Celiku; Alejandra Cavazos-Saldana; Aiguo Li; Yang Liu; Sue Han; Wei Zhang; Hua Song; Dionne Davis; Sunmin Lee; Jane B Trepel; Thais S Sabedot; Jeeva Munasinghe; Chunzhang Yang; Christel Herold-Mende; Mark R Gilbert; Murali Krishna Cherukuri; Houtan Noushmehr; Mioara Larion
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.